Biologics
Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...
September 18, 2025 | News
Skyhawk’s SKY-0515 Shows 62% Reduction in Mutant Huntingtin at Day 84 in Huntington’s Disease Trial
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional finding...
September 18, 2025 | News
Eli Lilly to Invest $5 Billion in New Virginia API and Bioconjugate Manufacturing Facility
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other ad...
September 17, 2025 | News
US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares
ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...
September 17, 2025 | News
China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...
September 17, 2025 | News
ProBioGen to Operate GMP Manufacturing Hub at Berlin’s New Gene and Cell Therapy Centre
ProBioGen and the Berlin Institute of Health at Charité (BIH) announced that ProBioGen has been selected to operate the process...
September 17, 2025 | News
Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...
September 16, 2025 | News
Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity
Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...
September 16, 2025 | News
BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...
September 16, 2025 | News
Single-Use Systems Are Rewiring Biopharma Manufacturing
Bioprocess, Unbottled Single-use systems (SUS) have become a transformative force in biopharmaceutical processing, offering an alternative to trad...
September 16, 2025 | Report
Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer
Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...
September 15, 2025 | News
Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma
Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...
September 15, 2025 | News
Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs
Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...
September 12, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
